Rotolo et al. show that immunocompetent dogs provide a reliable discovery platform to inform human clinical trials using allogeneic iNKT cells. Unedited iNKTs from an optimal donor persist and remain functional in MHC-unmatched recipients without requiring high-intensity preconditioning. This work supports the feasibility of globally accessible iNKT-based allogeneic therapies.
All Keywords
【저자키워드】 Biomarkers, Donor selection, Canine model, allogeneic invariant natural killer T, donor-recipient MHC mismatch, off-the-shelf adoptive cell therapy,
【저자키워드】 Biomarkers, Donor selection, Canine model, allogeneic invariant natural killer T, donor-recipient MHC mismatch, off-the-shelf adoptive cell therapy,